Investment analysts at StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Trading Down 2.4 %
Shares of NASDAQ EVOK opened at $5.19 on Friday. The business has a 50-day moving average price of $4.81 and a two-hundred day moving average price of $5.65. The firm has a market capitalization of $44.62 million, a PE ratio of -2.84 and a beta of 0.39. Evoke Pharma has a one year low of $3.54 and a one year high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last posted its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The business had revenue of $2.55 million during the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
See Also
- Five stocks we like better than Evoke Pharma
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
- What Are Some of the Best Large-Cap Stocks to Buy?
- China’s EV Rally: Should Investors Chase, Avoid, or Buy the Dip?
- How to Read Stock Charts for Beginners
- MarketBeat Week in Review – 10/7 – 10/11
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.